M034: PHARMACOKINETICS OF CIPROFLOXACIN IN CHILDREN WITH CYSTIC
FIBROSIS
C. MONTES*, A. MUNCK, M. GERARDIN, M. LEBOURGEOIS,
M. POPON*, M. GIROD*, J. NAVARRO, E. JACQZ AIGRAIN* (Pediatric
Clinical Pharmacology and Gastro-enterology, Hopital Robert Debr6,
Paris, France)
Ciprofloxacin (C1P) is a fluoroquinolone antibiotic active against Pseudomonas Aeruginosa, frequently responsible for bronchopulrnonary infections in patients with cystic fibrosis. The pharmacokinetic profiles of CIP were studied during the first day of treatment, in nine children (5-14 years) with cystic fibrosis. They received 10 mg/kg intravenous infusion over 30 min followed 12 hours latter by the oral administration of 15 mg/kg. Blood samples were collected during the 24 hour study at 0, 0.5, 1, 2, 4, S, 12 hours (after the IV administration) and at 13, 14, 16, 18, 22, 24 hours (after the oral dose). Ciprofloxacin concentrations in plasma were determined by high performance liquid chromatography.
The pharmacokinetic parameters were calculated using non compartmental methods: Cmax, Tmax, area under the plasma CIP concentration-time curve from time of administration to infinity (AUC), clearance (Cl), volume of distribution at steady-state (Vdss), dimination half-life, mean residence time (MRT) and bioavailability (F). Results are expressed as mean SD.
Conclusion: In patients with cystic fibrosis, CIP was well absorbed and rapidly eliminated. Elimination half-life was longer after oral than after IV administration (Student t test, p< 0.01). This is probably related to slow absorption, as reflected by the mean absorption time of 3.75 1.39 h
Parameters IV Administration Oral administration Dose (mglkg) 10 15 Cmax (mg/l) 4.84 0.99 1.74 0.51 Tmax (h) / 3.55 1.33 Auc (mg/lxh) 9.62 3.33 11.81 4.09 Cl (l/h/kg) 1 13 0.28 1.15 0.3 Vdss (I/kg) 2.69 0.5 2.74 0-5 Tl/2 (h) 2.22 0.4 3.21 0 9 MRT (h) 2.460.48 6.371.41 F (%) / 8314
Supported by a grant from l'Association Francaise de Lutte contre la Mucoviscidose